Clinical trial
Dose Rationale for Dapagliflozin and Empagliflozin in Paediatric Heart Failure: a Phase II.a Pharmacokinetics, Ease-of-swallow, Safety and Proof-of-concept Study Among Children 6-18 Years of Age
NCT06012266 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire Vaudois as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Dose Rationale for Dapagliflozin and Empagliflozin in Paediatric Heart Failure: a Phase II.a Pharmacokinetics, Ease-of-swallow, Safety and Proof-of-concept Study Among Children 6-18 Years of Age
- Lead sponsor
- Centre Hospitalier Universitaire Vaudois
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- August 31, 2024
- Completion date
- August 31, 2025
- Enrollment
- 12 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.